Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI
- How metformin controls blood glucose. Morris, David // GP: General Practitioner;3/25/2002, p56
Focuses on the efficacy of metformin in regulating glucose in the circulation. Administration of metformin in type-2 diabetic patients; Reduction of myocardial infarction; Mechanism of action.
- oral hypoglycaemic (Major drug group). // Royal Society of Medicine: Medicines;2002, p413
The article presents information on oral hypoglycaemic drugs which are usually synthetic agents taken by mouth to reduce the levels of glucose (sugar) in the bloodstream and are used mainly in the treatment of Type II diabetes (non-insulin-dependent diabetes mellitus; maturity-onset diabetes)...
- log(TG)/HDL-C is related to both residual cardiometabolic risk and Î²-cell function loss in type 2 diabetes males. Hermans, Michel P.; Ahn, Sylvie A.; Rousseau, Michel F. // Cardiovascular Diabetology;2010, Vol. 9, p88
Background: T2DM is associated with atherogenic dyslipidemia (AD), defined as decreased HDL-C plus raised triglycerides (TG). AD confers increased risk for CAD, even when LDL-C is at target. AD is rarely assessed due to lack of screening methods consensus. Aim: To establish the prevalence and...
- A Functional Tyr1306Cys Variant in LARG Is Associated With Increased Insulin Action in Vivo. Kovacs, Peter; Stumvoll, Michael; Bogardus, Clifton; Hanson, Robert L.; Baier, Leslie J. // Diabetes;May2006, Vol. 55 Issue 5, p1497
Diminished insulin sensitivity is a characteristic feature of type 2 diabetes. Inhibition of insulin action, resulting in reduced skeletal muscle glucose uptake, is mediated in part through stimulation of RhoA activity. One regulator of RhoA activity is leukemia-associated Rho guanine nucleotide...
- Treat all type 2 diabetes patients as if they had a history of prior MI. Haffner, S.M.; Lehto, S. // Geriatrics;Oct98, Vol. 53 Issue 10, p91
Reports that according to the authors of a study in Finland, aggressive treatment should be administered to cardiovascular risk factors in patients with type 2 diabetes who have not had a myocardial infarction (MI). Amount of participants in the study; Age range of the participants; Comparison...
- Ask Doctor Cory. SerVaas, Cory // Turtle;Jul/Aug2003, Vol. 25 Issue 4, p34
Addresses questions about diseases, such as heart attack and type 2 diabetes.
- Risks of treating diabetes 2. Napoli, Maryann // Center for Medical Consumers;Aug2011, p1
The article discusses the risks attendant to treating type 2 diabetes. A meta-analysis, which gathered clinical results from 13 randomized tests and published in the "British Medical Journal," shows that the drugs can cause risks leading to non-fatal or fatal heart diseases for diabetics who had...
- Third-line diabetes drugs offer comparable results. // Pulse;5/25/2011, Vol. 71 Issue 19, p9
The article discusses a study on the efficiency of third-line diabetes drugs on patients with type 2 diabetes wherein researchers reveal that there is no evident difference between drug classification on patients using metformin and sulfonylurea when added with a third agent.
- Troglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus. Plosker, G.L.; Faulds, D. // Drugs;Mar1999, Vol. 57 Issue 3, p409
Troglitazone is the first of a new group of oral antidiabetic drugs, the thiazolidinediones, and is indicated for the treatment of patients with type 2 (non-insulin-dependent) diabetes mellitus. Troglitazone acts by enhancing the effects of insulin at peripheral target sites and, unlike the...